Related Experiment Video
Updated: Mar 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit
Alejandro Álvaro-Meca1, María A Jiménez-Sousa2, Alexandre Boyer3
1Departamento de Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain.
Insights
Chronic hepatitis C (CHC) increases mortality risk in cirrhotic patients admitted to the intensive care unit (ICU). This risk is particularly elevated for CHC patients with compensated cirrhosis who develop severe sepsis.
Area of Science:
- Hepatology
- Critical Care Medicine
- Infectious Diseases
Background:
- Cirrhosis and severe sepsis are known mortality predictors in ICUs.
- The impact of chronic hepatitis C (CHC) on ICU mortality in cirrhotic patients remains understudied.
- This study investigates CHC's influence on cirrhotic patient mortality, considering severe sepsis and cirrhosis severity.
Purpose of the Study:
- To determine the impact of CHC on mortality in cirrhotic patients admitted to the ICU.
- To analyze the interaction between CHC, severe sepsis, and cirrhosis stage on ICU outcomes.
Main Methods:
- Retrospective study of 1138 CHC-cirrhotic patients and 4127 controls from the Spanish Minimum Basic Data Set (2005-2010).
- Primary outcome: ICU mortality. Secondary outcomes: cumulative mortality rates at 7, 30, and 90 days.
- Adjusted hazard ratios (aHR) for death were estimated using a Bayesian competing risk model.
Main Results:
- CHC patients showed higher cumulative mortality at 7, 30, and 90 days compared to controls.
- CHC was associated with increased ICU mortality risk when severe sepsis was present (aHR=1.19).
- Patients with CHC and compensated cirrhosis experiencing severe sepsis had a significantly higher risk of death (aHR=1.35).
Conclusions:
- Chronic hepatitis C is linked to increased mortality in cirrhotic ICU patients.
- The risk is most pronounced in CHC patients with compensated cirrhosis who develop severe sepsis.
- Further research may explore targeted interventions for this high-risk group.
Background:
Cirrhosis and severe sepsis are factors associated with increased mortality in intensive care unit (ICU), but chronic hepatitis C (CHC) has been less studied in ICU. The aim of this study was to analyze the impact of CHC on the mortality of cirrhotic patients admitted to ICU according to severe sepsis and decompensated cirrhosis.
Methods:
We carried out a retrospective study based on CHC-cirrhotic patients (CHC-group) admitted to ICU (n = 1138) and recorded in the Spanish Minimum Basic Data Set (2005-2010). A control-group (randomly selected cirrhotic patients without HIV, HBV, or HCV infections) was also included (n = 4127). The primary outcome variable was ICU mortality. The cumulative mortality rate on days 7, 30, and 90 in patients admitted to the ICUs was calculated by dividing the number of deaths by the number of patients admitted to the ICU. The adjusted hazard ratio (aHR) for death in the ICU was estimated through a semi-parametric Bayesian model of competing risk.
Results:
The CHC-group had a higher cumulative incidence of severe sepsis than the control-group in compensated cirrhosis (37.4 vs. 31.1%; p = 0.024), but no differences between the CHC-group and the control-group in decompensated cirrhosis were found. Moreover, a higher cumulative incidence of severe sepsis was associated with decompensated cirrhosis compared to compensated cirrhosis in the control-group (40.1 vs. 31.1%; p < 0.001) whereas this was not observed in the CHC group (38.1 vs. 37.4%; p = 0.872). The CHC-group had higher cumulative mortality than the control-group by days 7 (47 vs. 41.3%; p < 0.001), 30 (78.5 vs. 73.5%; p < 0.001), and 90 (96.3 vs. 95.9%; p < 0.001). In a competitive risk model, the CHC-group had a higher risk of dying if the ICU course was complicated by severe sepsis (adjusted hazard ratio (aHR) = 1.19; p = 0.003), but no significant values in patients with absence of severe sepsis were found (aHR = 1.09; p= 0.068). When patients were stratified by cirrhosis stage and severe sepsis, CHC patients with compensated cirrhosis had the higher risk of death if they had severe sepsis (aHR = 1.35; p = 0.002). Moreover, the survival was low in patients with decompensated cirrhosis and severe sepsis but we did not find significant differences between CHC-group and control-group.
Conclusions:
CHC was associated with an increased risk of death in cirrhotic patients admitted to ICUs, particularly in patients with compensated cirrhosis and severe sepsis.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
